The D136A mutation of the V<sub>2</sub> vasopressin receptor induces a constitutive activity which permits discrimination between antagonists with partial agonist and inverse agonist activities

Denis Morin(Inserm), Nathalie de la Cotte(Inserm), Marie‐Noëlle Balestre(Inserm), Bernard Mouillac(Inserm), Maurice Manning(University of Toledo Medical Center), Christophe Breton(Inserm), Claude Barberis(Inserm)
FEBS Letters
December 28, 1998
Cited by 88Open Access
Full Text

Abstract

The substitution, in the human V2 vasopressin receptor, of the aspartate at position 136 by alanine leads to agonist-independent activation of this mutant V2 receptor. Pharmacological studies of the D136A V2 receptor helped us in characterizing different V2 receptor antagonists. SR-121463A and OPC-31260, two non-peptide antagonists, behaved as inverse agonists, while two cyclic peptides d(CH2)5[D-Tyr(Et)2,-Val4,Tyr-NH(2)9]AVP and d(CH2)5[D-Ile2,Ile4,Tyr-NH(2)9]AVP known to be V2 antagonists, demonstrated clear partial agonist properties. The finding of a constitutively activated human V2 receptor represents a useful tool in characterizing V2 receptor antagonist ligands.


Related Papers

No related papers found

Powered by citation graph analysis